Angelo Avogaro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2958486/publications.pdf

Version: 2024-02-01

360	19,894	10373	15249
papers	citations	72 h-index	126 g-index

376	376	376	21820
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance. Journal of Endocrinological Investigation, 2022, 45, 115-124.	1.8	12
2	Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an <scp>ITAS</scp> post hoc analysis. Diabetes, Obesity and Metabolism, 2022, 24, 327-331.	2.2	2
3	Hematopoietic and Nonhematopoietic p66Shc Differentially Regulates Stem Cell Traffic and Vascular Response to Ischemia in Diabetes. Antioxidants and Redox Signaling, 2022, 36, 593-607.	2.5	6
4	Challenges and opportunities in realâ€world evidence on the renal effects of sodiumâ€glucose cotransporterâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2022, 24, 177-186.	2.2	11
5	A novel MRPS34 gene mutation with combined OXPHOS deficiency in an adult patient with Leigh syndrome. Molecular Genetics and Metabolism Reports, 2022, 30, 100830.	0.4	1
6	Effectiveness of remote screening for diabetic retinopathy among patients referred to Mozambican Diabetes Association (AMODIA): a retrospective observational study. Acta Diabetologica, 2022, 59, 563.	1.2	1
7	Anthropometrics, Dietary Intake and Body Composition in Urea Cycle Disorders and Branched Chain Organic Acidemias: A Case Study of 18 Adults on Low-Protein Diets. Nutrients, 2022, 14, 467.	1.7	2
8	Response to Chia Siang Kow and colleagues. Acta Diabetologica, 2022, 59, 287.	1.2	0
9	Hyperglycemia, Reduced Hematopoietic Stem Cells, and Outcome of COVID-19. Diabetes, 2022, 71, 788-794.	0.3	8
10	Glycemic control after switching to faster aspart in adults with type 1 diabetes. Journal of Endocrinological Investigation, 2022, 45, 1181-1188.	1.8	3
11	In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study. Scientific Reports, 2022, 12, 3474.	1.6	8
12	The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis. International Journal of Cardiology, 2022, 357, 123-127.	0.8	2
13	EMG analysis across different tasks improves prevention screenings in diabetes: a cluster analysis approach. Medical and Biological Engineering and Computing, 2022, 60, 1659.	1.6	1
14	Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care. Acta Diabetologica, 2022, 59, 921-928.	1.2	4
15	Performance assessment across different care settings of a heart failure hospitalisation risk-score for type 2 diabetes using administrative claims. Scientific Reports, 2022, 12, 7762.	1.6	1
16	Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes. Computer Methods and Programs in Biomedicine, 2022, 221, 106873.	2.6	3
17	A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease. Diabetologia, 2022, 65, 1555-1568.	2.9	5
18	Assessment of simple strategies for identifying undiagnosed diabetes and prediabetes in the general population. Journal of Endocrinological Investigation, 2021, 44, 75-81.	1.8	4

#	Article	IF	Citations
19	Effects of glucose variability on hematopoietic stem/progenitor cells in patients with type 1 diabetes. Journal of Endocrinological Investigation, 2021, 44, 119-126.	1.8	8
20	Comparative effectiveness of dapagliflozin vs <scp>DPP</scp>â€4 inhibitors on a composite endpoint of <scp>HbA1c</scp>, body weight and blood pressure reduction in the real world. Diabetes/Metabolism Research and Reviews, 2021, 37, e3353.	1.7	17
21	Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies. Journal of Endocrinological Investigation, 2021, 44, 745-753.	1.8	9
22	Cardiac injury and mortality in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis. Internal and Emergency Medicine, 2021, 16, 419-427.	1.0	31
23	Comparing the accuracy of transcutaneous sensor and 90-day implantable glucose sensor. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 650-657.	1.1	7
24	SARS CoV2 infection in a young subject affected by arginosuccinate synthase deficiency: A case report of epilepsy worsening. Molecular Genetics and Metabolism Reports, 2021, 26, 100698.	0.4	2
25	The Toll of Lockdown Against COVID-19 on Diabetes Outpatient Care: Analysis From an Outbreak Area in Northeast Italy. Diabetes Care, 2021, 44, e18-e21.	4.3	31
26	Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown. Nutrition and Diabetes, 2021, 11, 1.	1.5	30
27	Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. Journal of Endocrinological Investigation, 2021, 44, 1879-1889.	1.8	24
28	Recurrent Neural Network to Predict Renal Function Impairment in Diabetic Patients via Longitudinal Routine Check-up Data. Lecture Notes in Computer Science, 2021, , 329-337.	1.0	0
29	Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS. Acta Diabetologica, 2021, 58, 789-796.	1.2	0
30	SGLT-2Âinhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovascular Diabetology, 2021, 20, 39.	2.7	35
31	The â€œEarly Treatmentâ€•Approach Reducing Cardiovascular Risk in Patients with TypeÂ2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. Diabetes Therapy, 2021, 12, 1445-1461.	1.2	5
32	Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care. Diabetes Research and Clinical Practice, 2021, 173, 108686.	1.1	6
33	Where diabetes care meets cardiovascular research: our cardiovascular perspective at a Centre devoted to diabetes research and care. European Heart Journal, 2021, 42, 2417-2419.	1.0	0
34	Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 217-240.	2.6	19
35	Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy. Journal of Clinical Medicine, 2021, 10, 1288.	1.0	10
36	Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis. Diabetes, 2021, 70, 1767-1779.	0.3	17

#	Article	IF	Citations
37	Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 453-464.	0.7	2
38	SGLT2 inhibitors: Do we need other evidences?. European Journal of Internal Medicine, 2021, 87, 18-19.	1.0	0
39	Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 103.	2.7	3
40	A simple way to spotlight hidden heart failure in type 2 diabetes?. European Journal of Heart Failure, 2021, 23, 1094-1096.	2.9	1
41	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	1.1	5
42	Managing diabetes in diabetic patients with COVID: where do we start from?. Acta Diabetologica, 2021, 58, 1441-1450.	1.2	5
43	High prolactin levels in dihydropteridine reductase deficiency: A sign of therapy failure or additional pathology?. JIMD Reports, 2021, 61, 48-51.	0.7	4
44	Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targetsâ€™ attainment in subjects with and without type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 144.	2.7	17
45	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3257-3270.	1.1	7
46	Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial. Diabetologia, 2021, 64, 2334-2344.	2.9	9
47	Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies. Diabetes Research and Clinical Practice, 2021, 179, 109024.	1.1	6
48	Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3474-3483.	1.1	7
49	Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. Journal of Endocrinological Investigation, 2021, 44, 1379-1386.	1.8	35
50	Why diabetes outpatient clinics should not close during pandemic crises. Journal of Endocrinological Investigation, 2021, 44, 1795-1798.	1.8	1
51	Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. European Journal of Preventive Cardiology, 2021, 28, 22-29.	0.8	12
52	Effects of the chymase inhibitor fulacimstat in diabetic kidney diseaseâ€"results from the CADA DIA trial. Nephrology Dialysis Transplantation, 2021, 36, 2263-2273.	0.4	12
53	Coronary perivascular inflammation in type 2 diabetes mellitus patients: the missing piece in the puzzle of their increased cardiovascular risk?. European Heart Journal, 2021, 42, .	1.0	0
54	105.3: Analysis of Autoimmune Re-activation After COVID-19 mRNA Vaccination in Pancreas Transplant Recipients. Transplantation, 2021, 105, S2-S2.	0.5	2

#	Article	IF	Citations
55	Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study. Cardiovascular Diabetology, 2021, 20, 222.	2.7	7
56	Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study. Journal of Endocrinological Investigation, 2020, 43, 329-336.	1.8	9
57	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
58	Trend 2010â€“2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. Acta Diabetologica, 2020, 57, 367-375.	1.2	20
59	Diabetes diagnosis from administrative claims and estimation of the true prevalence of diabetes among 4.2 million individuals of the Veneto region (North East Italy). Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 84-91.	1.1	33
60	Reinterpreting Cardiorenal Protection of Renal Sodiumâ€“Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming. Diabetes Care, 2020, 43, 501-507.	4.3	36
61	Estradiol correlates with erectile dysfunction and its severity in type 2 diabetic patients. Journal of Diabetes and Its Complications, 2020, 34, 107728.	1.2	2
62	The hazard of (sub)therapeutic doses of anticoagulants in nonâ€critically ill patients with Covidâ€19: The Padua province experience. Journal of Thrombosis and Haemostasis, 2020, 18, 2629-2635.	1.9	71
63	Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4221-4234.	1.1	13
64	Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics. Cardiovascular Diabetology, 2020, 19, 190.	2.7	22
65	Exposure to dipeptidylâ€peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1925-1934.	2.2	14
66	Performance of the Steno type 1 risk engine for cardiovascular disease prediction in Italian patients with type 1 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1813-1819.	1.1	15
67	Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. Diabetes Therapy, 2020, 11, 2629-2645.	1.2	14
68	Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Research and Clinical Practice, 2020, 168, 108374.	1.1	147
69	Pharmacologic PPAR-Î³ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes. Diabetes, 2020, 69, 1562-1572.	0.3	18
70	Cardiovascular and heart failure outcomes with type 2 diabetes therapies: how important is weight loss?. Lancet Diabetes and Endocrinology,the, 2020, 8, 353-355.	5.5	4
71	Euglycemic Ketoacidosis. Current Diabetes Reports, 2020, 20, 25.	1.7	19
72	Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy. Diabetes Therapy, 2020, 11, 1369-1379.	1.2	150

#	Article	IF	Citations
73	Stem cell mobilization with plerixafor and healing of diabetic ischemic wounds: A phase IIa , randomized, doubleâ€blind , placeboâ€controlled trial. Stem Cells Translational Medicine, 2020, 9, 965-973.	1.6	13
74	Exposure to dipeptidylâ€peptidaseâ€4 inhibitors and <scp>COVID</scp>â€19 among people with type 2 diabetes: A caseâ€control study. Diabetes, Obesity and Metabolism, 2020, 22, 1946-1950.	2.2	91
75	Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. Cardiovascular Diabetology, 2020, 19, 74.	2.7	26
76	Diabetic retinopathy: looking beyond the eyes. Diabetologia, 2020, 63, 1662-1664.	2.9	11
77	Prevalence and impact of diabetes among people infected with SARS-CoV-2. Journal of Endocrinological Investigation, 2020, 43, 867-869.	1.8	371
78	Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Research and Care, 2020, 8, e001451.	1.2	48
79	Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. Metabolism: Clinical and Experimental, 2020, 106, 154190.	1.5	20
80	Comparable efficacy with similarly low risk of hypoglycaemia in patientâ€vs physicianâ€managed basal insulin initiation and titration in insulinâ€naÃ¯ve type 2 diabetic subjects: The Italian Titration Approach Study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3304.	1.7	11
81	Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagonâ€like peptideâ€1 receptor agonists. Diabetes, Obesity and Metabolism, 2020, 22, 817-827.	2.2	19
82	Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 161-174.	1.1	105
83	Highâ€protein diet: A barrier to the nephroprotective effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors?. Diabetes, Obesity and Metabolism, 2020, 22, 1511-1515.	2.2	4
84	Diabetes mellitus impairs circulating proangiogenic granulocytes. Diabetologia, 2020, 63, 1872-1884.	2.9	13
85	Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2617-e2625.	1.8	17
86	Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2464-2474.	1.8	7
87	Diabetes and the Cardiovascular System. Endocrinology, 2020, , 131-159.	0.1	0
88	Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. Journal of Endocrinological Investigation, 2019, 42, 345-349.	1.8	11
89	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 252-260.	2.2	33
90	Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Cardiovascular Diabetology, 2019, 18, 106.	2.7	21

#	Article	IF	Citations
91	Fixed versus flexible combination of GLPâ€1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes, Obesity and Metabolism, 2019, 21, 2542-2552.	2.2	19
92	Diabetes and the Cardiovascular System. Endocrinology, 2019, , 1-29.	0.1	0
93	One-year caloric restriction and 12-week exercise training intervention in obese adults with type 2 diabetes: emphasis on metabolic control and resting metabolic rate. Journal of Endocrinological Investigation, 2019, 42, 1497-1507.	1.8	5
94	Changes in the Prescription of Glucoseâ€Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. Journal of the American Heart Association, 2019, 8, e012244.	1.6	8
95	Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity. International Journal of Molecular Sciences, 2019, 20, 4966.	1.8	21
96	Angiogenic Abnormalities in Diabetes Mellitus: Mechanistic and Clinical Aspects. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5431-5444.	1.8	64
97	Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study. Cardiovascular Diabetology, 2019, 18, 117.	2.7	11
98	Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetologica, 2019, 56, 1051-1060.	1.2	10
99	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diabetes and Vascular Disease Research, 2019, 16, 399-414.	0.9	26
100	Similar effectiveness of dapagliflozin and GLPâ€1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 1886-1894.	2.2	17
101	Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes. Journal of Endocrinological Investigation, 2019, 42, 1099-1107.	1.8	13
102	Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway. Diabetes, 2019, 68, 1303-1314.	0.3	47
103	Italian Titration Approach Study (ITAS) with insulin glargine 300ÂU/mL in insulin-naÃ¯ve type 2 diabetes: Design and population. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 496-503.	1.1	7
104	Ultrasound Tissue Characterization of Carotid Plaques Differs Between Patients with Type 1 Diabetes and Subjects without Diabetes. Journal of Clinical Medicine, 2019, 8, 424.	1.0	8
105	The use of real time continuous glucose monitoring or flash glucose monitoring in the management of diabetes: A consensus view of Italian diabetes experts using the Delphi method. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 421-431.	1.1	52
106	Microvascular complications in diabetes: A growing concern for cardiologists. International Journal of Cardiology, 2019, 291, 29-35.	0.8	93
107	Pharmacovigilance assessment of the association between Fournierâ€™s gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Research and Care, 2019, 7, e000725.	1.2	26
108	Comparative effectiveness of exenatide onceâ€weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and metaâ€analysis of observational studies. Diabetes, Obesity and Metabolism, 2019, 21, 1255-1260.	2.2	10

#	Article	IF	Citations
109	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetologica, 2019, 56, 605-617.	1.2	50
110	Diabetes and the Cardiovascular System. Endocrinology, 2019, , 1-29.	0.1	0
111	Diabetic retinopathy: a tool for cardiovascular risk stratification. Diabetes Mellitus, 2019, 22, 455-460.	0.5	0
112	Insulin treatment in patients with diabetes andÂheart failure: defendant on the stand. European Journal of Heart Failure, 2018, 20, 896-897.	2.9	2
113	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes, Obesity and Metabolism, 2018, 20, 1781-1786.	2.2	32
114	The pleiotropic cardiovascular effects of dipeptidyl peptidaseâ€4 inhibitors. British Journal of Clinical Pharmacology, 2018, 84, 1686-1695.	1.1	23
115	The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetologica, 2018, 55, 593-601.	1.2	103
116	Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. BMJ Open Diabetes Research and Care, 2018, 6, e000475.	1.2	26
117	Head-to-head comparison of the accuracy of Abbott FreeStyle Libre and Dexcom G5 mobile. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 425-427.	1.1	42
118	Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. Diabetes, Obesity and Metabolism, 2018, 20, 1367-1368.	2.2	5
119	FreeStyle Libre and Dexcom G4 Platinum sensors: Accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 180-186.	1.1	50
120	Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. Diabetes and Metabolism, 2018, 44, 333-340.	1.4	5
121	Keeping the right track in the treatment of patients with type 2 diabetes. European Journal of Heart Failure, 2018, 20, 52-54.	2.9	2
122	When metformin is not enough: Pros and cons of SGLT2 and DPPâ€4 inhibitors as a second line therapy. Diabetes/Metabolism Research and Reviews, 2018, 34, e2981.	1.7	23
123	Effects of Hypoglycemia on Circulating Stem and Progenitor Cells in Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1048-1055.	1.8	8
124	Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. Diabetes Therapy, 2018, 9, 851-861.	1.2	14
125	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and diabetic ketoacidosis: <scp>A</scp>n updated review of the literature. Diabetes, Obesity and Metabolism, 2018, 20, 25-33.	2.2	76
126	Dipeptidyl peptidaseâ€4 inhibitors moderate the risk of genitourinary tract infections associated with sodiumâ€glucose coâ€transporterâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2018, 20, 740-744.	2.2	31

#	Article	IF	Citations
127	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2018, 9, 27-36.	1.2	5
128	Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3773-3782.	1.8	29
129	Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. Acta Diabetologica, 2018, 55, 1121-1129.	1.2	2
130	Characteristics, prevalence, and outcomes of diabetic foot ulcers in Africa. A systemic review and meta-analysis. Diabetes Research and Clinical Practice, 2018, 142, 63-73.	1.1	42
131	Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. Diabetes Therapy, 2018, 9, 1477-1490.	1.2	12
132	Interplay between gut microbiota and p66Shc affects obesityâ€associated insulin resistance. FASEB Journal, 2018, 32, 4004-4015.	0.2	17
133	Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes. Cardiovascular Diabetology, 2018, 17, 66.	2.7	36
134	p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications. Cardiovascular Diabetology, 2018, 17, 16.	2.7	12
135	How to interpret the role of SDF-1Î± on diabetic complications during therapy with DPP-4 inhibitors. Cardiovascular Diabetology, 2018, 17, 22.	2.7	6
136	Impaired cognitive processing speed in type 1 diabetic patients who had severe/recurrent hypoglycaemia. Journal of Diabetes and Its Complications, 2018, 32, 1040-1045.	1.2	9
137	Diabetes and the Cardiovascular System. Endocrinology, 2018, , 1-29.	0.1	0
138	Systemic and vascular inflammation in an in-vitro model of central obesity. PLoS ONE, 2018, 13, e0192824.	1.1	27
139	Diabetes and the Cardiovascular System. Endocrinology, 2018, , 131-159.	0.1	0
140	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications. Diabetes Mellitus, 2018, 21, 376-385.	0.5	0
141	DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes. Cardiovascular Diabetology, 2017, 16, 22.	2.7	13
142	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2017, 18, 517-527.	0.9	5
143	A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Review of Clinical Pharmacology, 2017, 10, 763-772.	1.3	14
144	Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidaseâ€4 inhibitor or a sulphonylurea: <scp>R</scp>esults from the <scp>OsMed H</scp>ealthâ€<scp>DB</scp> registry. Diabetes, Obesity and Metabolism, 2017, 19, 1416-1424.	2.2	18

#	Article	IF	Citations
145	A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy. Journal of Diabetes and Its Complications, 2017, 31, 1348-1353.	1.2	34
146	Persistent Reduction of Circulating Myeloid Calcifying Cells in Acromegaly: Relevance to the Boneâ€“Vascular Axis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2044-2050.	1.8	1
147	SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia, 2017, 60, 1385-1389.	2.9	186
148	Re: â€œPlasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitusâ€• by Bayomi et al. (Metab Syndr Relat Disord 2017;15:269â€“275). Metabolic Syndrome and Related Disorders, 2017, 15, 266-268.	0.5	1
149	Mechanisms linking empagliflozin to cardiovascular and renal protection. International Journal of Cardiology, 2017, 241, 450-456.	0.8	36
150	Silent coronary heart disease in patients with type 2 diabetes: application of a screening approach in a follow-up study. Journal of Diabetes and Its Complications, 2017, 31, 952-957.	1.2	5
151	The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography. Journal of Endocrinological Investigation, 2017, 40, 627-634.	1.8	5
152	Influence of health locus of control and fear of hypoglycaemia on glycaemic control and treatment satisfaction in people with Type 1 diabetes on insulin pump therapy. Diabetic Medicine, 2017, 34, 691-697.	1.2	19
153	Reduced circulating stem cells associate with excess fasting and post-load NEFA exposure in healthy adults with normal glucose tolerance. Atherosclerosis, 2017, 261, 117-123.	0.4	4
154	Shift of monocyte subsets along their continuum predicts cardiovascular outcomes. Atherosclerosis, 2017, 266, 95-102.	0.4	42
155	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. Cardiovascular Research, 2017, 113, 1627-1638.	1.8	62
156	Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1089-1097.	1.1	26
157	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	5.5	231
158	SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes and Endocrinology,the, 2017, 5, 680-681.	5.5	113
159	Cognitive, neurophysiologic and metabolic sequelae of previous hypoglycemic coma revealed by hyperinsulinemic-hypoglycemic clamp in type 1 diabetic patients. Metabolic Brain Disease, 2017, 32, 1543-1551.	1.4	3
160	Comparison of lower limb muscle strength between diabetic neuropathic and healthy subjects using OpenSim. Gait and Posture, 2017, 58, 194-200.	0.6	21
161	Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3674-3682.	1.8	22
162	Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovascular Diabetology, 2017, 16, 42.	2.7	80

#	Article	IF	Citations
163	Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 125-131.	4.3	79
164	The rs2274911 polymorphism in <scp>GPRC</scp>6A gene is associated with insulin resistance in normal weight and obese subjects. Clinical Endocrinology, 2017, 86, 185-191.	1.2	28
165	Psychological outcomes of evening and night closedâ€loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2â€month randomized crossover trial. Diabetic Medicine, 2017, 34, 262-271.	1.2	33
166	Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance. Cardiovascular Diabetology, 2017, 16, 118.	2.7	55
167	Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe. Diabetes Care, 2016, 39, 1180-1185.	4.3	79
168	Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home. Diabetes Care, 2016, 39, 1151-1160.	4.3	98
169	Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and Death. Circulation Research, 2016, 118, 1930-1939.	2.0	97
170	Plerixafor improves the endothelial health balance. The effect of diabetes analysed by polychromatic flow cytometry. Atherosclerosis, 2016, 251, 373-380.	0.4	10
171	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovascular Diabetology, 2016, 15, 111.	2.7	44
172	Altered EMG patterns in diabetic neuropathic and not neuropathic patients during step ascending and descending. Journal of Electromyography and Kinesiology, 2016, 31, 32-39.	0.7	13
173	Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. Diabetes Therapy, 2016, 7, 679-693.	1.2	13
174	Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1112-1119.	1.1	25
175	Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes. Journal of Endocrinological Investigation, 2016, 39, 1391-1399.	1.8	83
176	Hypovitaminosis D is associated with erectile dysfunction in type 2 diabetes. Endocrine, 2016, 53, 831-838.	1.1	19
177	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 85-102.	1.1	9
178	Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 748-756.	1.8	65
179	Blood expression of matrix metalloproteinases 8 and 9 and of their inducers S100A8 and S100A9 supports diagnosis and prognosis of PDAC-associated diabetes mellitus. Clinica Chimica Acta, 2016, 456, 24-30.	0.5	15
180	A perspective on NETosis in diabetes and cardiometabolic disorders. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1-8.	1.1	45

#	Article	IF	Citations
181	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushingâ€™s syndrome and acromegaly. Journal of Endocrinological Investigation, 2016, 39, 235-255.	1.8	30
182	NETosis Delays Diabetic Wound Healing in Mice and Humans. Diabetes, 2016, 65, 1061-1071.	0.3	233
183	GAIT ANALYSIS DRIVEN 2D FINITE ELEMENT MODEL OF THE NEUROPATHIC HINDFOOT. Journal of Mechanics in Medicine and Biology, 2016, 16, 1650012.	0.3	1
184	Hypovitaminosis D is associated with lower urinary tract symptoms and benign prostate hyperplasia in type 2 diabetes. Andrology, 2015, 3, 1062-1067.	1.9	12
185	Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients. Vascular Pharmacology, 2015, 67-69, 21-29.	1.0	14
186	Circulating Stem Cells Associate With Adiposity and Future Metabolic Deterioration in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4570-4578.	1.8	18
187	Sensory neuropathy hampers nociception-mediated bone marrow stem cell release in mice and patients with diabetes. Diabetologia, 2015, 58, 2653-2662.	2.9	33
188	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients WithÂHeart Failure. JACC: Heart Failure, 2015, 3, 136-145.	1.9	265
189	Alternative Activation of Human Macrophages Is Rescued by Estrogen Treatment In Vitro and Impaired by Menopausal Status. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E50-E58.	1.8	89
190	Dipeptidyl peptidaseâ€4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 107-115.	2.2	32
191	Hypoglycemia affects the changes in endothelial progenitor cell levels during insulin therapy in type 2 diabetic patients. Journal of Endocrinological Investigation, 2015, 38, 733-738.	1.8	12
192	Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. Vascular Pharmacology, 2015, 73, 1-3.	1.0	17
193	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. European Heart Journal, 2015, 36, 2454-2462.	1.0	94
194	Diabetes modifies the relationships among carotid plaque calcification, composition and inflammation. Atherosclerosis, 2015, 241, 533-538.	0.4	11
195	High Temporal Resolution Detection of Patient-Specific Glucose Uptake from Human ex Vivo Adipose Tissue On-Chip. Analytical Chemistry, 2015, 87, 6535-6543.	3.2	26
196	Bone Marrow Macrophages Contribute to Diabetic Stem Cell Mobilopathy by Producing Oncostatin M. Diabetes, 2015, 64, 2957-2968.	0.3	85
197	Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 686-693.	1.1	71
198	Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. Diabetes, 2015, 64, 2969-2977.	0.3	50

#	Article	IF	Citations
199	NAD+-dependent SIRT1 deactivation has a key role on ischemiaâ€“reperfusion-induced apoptosis. Vascular Pharmacology, 2015, 70, 35-44.	1.0	48
200	2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 939-947.	5.5	189
201	Effects of dose escalating liraglutide from 1.2 to 1.8Âmg in clinical practice: a caseâ€“control study. Journal of Endocrinological Investigation, 2015, 38, 1357-1363.	1.8	7
202	Circulating Progenitor Cell Count Predicts Microvascular Outcomes in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2666-2672.	1.8	85
203	Carotid Plaque Calcification Predicts Future Cardiovascular Events in Type 2 Diabetes. Diabetes Care, 2015, 38, 1937-1944.	4.3	43
204	p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans. Diabetologia, 2015, 58, 2352-2360.	2.9	29
205	Effects of Age, Diabetes, and Vascular Disease on Growth Differentiation Factor 11: First-in-Human Study. Diabetes Care, 2015, 38, e118-e119.	4.3	12
206	NETosis is induced by high glucose and associated with type 2 diabetes. Acta Diabetologica, 2015, 52, 497-503.	1.2	188
207	Mechanisms of ectopic calcification: implications for diabetic vasculopathy. Cardiovascular Diagnosis and Therapy, 2015, 5, 343-52.	0.7	25
208	Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection. Current Pharmaceutical Design, 2014, 20, 2387-2394.	0.9	38
209	Sirtuin 1 stabilization by HuR represses TNF-Î±- and glucose-induced E-selectin release and endothelial cell adhesivenessinÂvitro: relevance to human metabolic syndrome. Clinical Science, 2014, 127, 449-461.	1.8	35
210	Endothelial Progenitor Cells Are Reduced in Acromegalic Patients and Can Be Restored by Treatment With Somatostatin Analogs. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2549-E2556.	1.8	8
211	Ectopic calcification in diabetic vascular disease. Expert Opinion on Therapeutic Targets, 2014, 18, 595-609.	1.5	13
212	Diabetes Causes Bone Marrow Autonomic Neuropathy and Impairs Stem Cell Mobilization via Dysregulated p66Shc and Sirt1. Diabetes, 2014, 63, 1353-1365.	0.3	131
213	Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis. Atherosclerosis, 2014, 237, 805-808.	0.4	76
214	3D finite element model of the diabetic neuropathic foot: A gait analysis driven approach. Journal of Biomechanics, 2014, 47, 3064-3071.	0.9	41
215	The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications. Diabetes Care, 2014, 37, 2884-2894.	4.3	138
216	Identification of diabetic neuropathic patients at risk of foot ulceration through finite element models and cluster analysis. Journal of Foot and Ankle Research, 2014, 7, .	0.7	1

#	Article	IF	Citations
217	Biomechanical evaluation of diabetic foot through hierarchical cluster analysis. Journal of Foot and Ankle Research, 2014, 7, .	0.7	0
218	2â€Dimensional foot FE models for clinical application in gait analysis. Journal of Foot and Ankle Research, 2014, 7, .	0.7	0
219	Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy. Current Diabetes Reports, 2014, 14, 483.	1.7	26
220	The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. Cardiovascular Diabetology, 2014, 13, 92.	2.7	25
221	Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in type 2 diabetic patients. Atherosclerosis, 2014, 235, 415-417.	0.4	18
222	Restoring stem cell mobilization to promote vascular repair in diabetes. Vascular Pharmacology, 2013, 58, 253-258.	1.0	24
223	An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia, 2013, 56, 1856-1866.	2.9	119
224	Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetologica, 2013, 50, 943-949.	1.2	46
225	Myeloid calcifying cells promote atherosclerotic calcification via paracrine activity and allograft inflammatory factor-1 overexpression. Basic Research in Cardiology, 2013, 108, 368.	2.5	28
226	Achieving glycemic control in patients with type 2 diabetes and renal impairment. Acta Diabetologica, 2013, 50, 283-291.	1.2	23
227	The Endothelium Abridges Insulin Resistance to Premature Aging. Journal of the American Heart Association, 2013, 2, e000262.	1.6	26
228	The role of foot morphology on foot function in diabetic subjects with or without neuropathy. Gait and Posture, 2013, 37, 603-610.	0.6	38
229	Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans. Diabetes Care, 2013, 36, 943-949.	4.3	151
230	The limited clinical value of a specific diabetic cardiomyopathy. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 599-605.	1.1	3
231	Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Research in Cardiology, 2013, 108, 313.	2.5	63
232	Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease. International Journal of Cardiology, 2013, 168, 892-897.	0.8	42
233	Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis, 2013, 229, 23-29.	0.4	48
234	Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opinion on Therapeutic Targets, 2013, 17, 739-742.	1.5	10

#	Article	IF	Citations
235	Circulating myeloid calcifying cells have antiangiogenic activity via thrombospondinâ€1 overexpression. FASEB Journal, 2013, 27, 4355-4365.	0.2	23
236	It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	41
237	Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery Disease. Experimental Diabetes Research, 2012, 2012, 1-7.	3.8	42
238	Elevated white blood cell count is associated with prevalence and development of the metabolic syndrome and its components in the general population. Acta Diabetologica, 2012, 49, 445-451.	1.2	36
239	Abnormal muscle activation during gait in diabetes patients with and without neuropathy. Gait and Posture, 2012, 35, 101-105.	0.6	101
240	Integrated kinematicsâ€“kineticsâ€“plantar pressure data analysis: A useful tool for characterizing diabetic foot biomechanics. Gait and Posture, 2012, 36, 20-26.	0.6	76
241	Endothelial progenitor cells in diabetes mellitus. BioFactors, 2012, 38, 194-202.	2.6	73
242	Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes, Obesity and Metabolism, 2012, 14, 14-19.	2.2	22
243	The increased dipeptidyl peptidaseâ€4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metforminâ€treated patients. Diabetes, Obesity and Metabolism, 2012, 14, 518-522.	2.2	49
244	Which is the eligible patient to be treated with pioglitazone? The expert view. Journal of Endocrinological Investigation, 2011, 34, 781-787.	1.8	1
245	Endothelial Dysfunction in Diabetes. Diabetes Care, 2011, 34, S285-S290.	4.3	381
246	Impaired endothelial progenitor cell recruitment may contribute to heart transplant microvasculopathy. Journal of Heart and Lung Transplantation, 2011, 30, 70-76.	0.3	14
247	Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes, Obesity and Metabolism, 2011, 13, 718-725.	2.2	50
248	At the crossroads of longevity and metabolism: the metabolic syndrome and lifespan determinant pathways. Aging Cell, 2011, 10, 10-17.	3.0	88
249	Comments on the article â€œEffects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuationsâ€•by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79â€“83). Journal of Diabetes and Its Complications, 2011, 25, 352-353.	1.2	4
250	Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1. Vascular Pharmacology, 2011, 55, 10-16.	1.0	189
251	Defective recruitment, survival and proliferation of bone marrow-derived progenitor cells at sites of delayed diabetic wound healing in mice. Diabetologia, 2011, 54, 945-953.	2.9	70
252	PS12 - 62. Continuous glucose monitoring accuracy assessed at home is seemingly better than when assessed at the clinical research centre. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 133-133.	0.0	0

#	Article	IF	Citations
253	Widespread Increase in Myeloid Calcifying Cells Contributes to Ectopic Vascular Calcification in Type 2 Diabetes. Circulation Research, 2011, 108, 1112-1121.	2.0	109
254	Insulin signaling and life span. Pflugers Archiv European Journal of Physiology, 2010, 459, 301-314.	1.3	56
255	Insulin sensitivity and secretion in young, healthy subjects are not changed by Zone and Mediterranean diets. Mediterranean Journal of Nutrition and Metabolism, 2010, 3, 233-237.	0.2	2
256	Improved Function of Circulating Angiogenic Cells Is Evident in Type 1 Diabetic Islet-Transplanted Patients. American Journal of Transplantation, 2010, 10, 2690-2700.	2.6	22
257	Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes, Obesity and Metabolism, 2010, 12, 570-583.	2.2	76
258	Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms. Diabetes, 2010, 59, 1006-1015.	0.3	268
259	The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, 1607-1609.	4.3	299
260	The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing. Diabetes, 2010, 59, 2306-2314.	0.3	83
261	Time Course and Mechanisms of Circulating Progenitor Cell Reduction in the Natural History of Type 2 Diabetes. Diabetes Care, 2010, 33, 1097-1102.	4.3	168
262	Cell-based methods for ex vivo evaluation of human endothelial biology. Cardiovascular Research, 2010, 87, 12-21.	1.8	52
263	Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy. Diabetes, 2010, 59, 2152-2159.	0.3	139
264	Two Cases of Statin-Induced Rhabdomyolysis Associated with Mononeuropathy. Clinical Drug Investigation, 2010, 30, 347-350.	1.1	8
265	Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biology International, 2010, 34, 709-715.	1.4	23
266	Microangiopathy is independently associated with presence, severity and composition of carotid atherosclerosis in type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 21, 286-93.	1.1	34
267	Reduced endothelial progenitor cells and brachial artery flowâ€mediated dilation as evidence of endothelial dysfunction in ocular hypertension and primary openâ€angle glaucoma. Acta Ophthalmologica, 2010, 88, 135-141.	0.6	56
268	Autologous stem cell therapy for peripheral arterial disease. Atherosclerosis, 2010, 209, 10-17.	0.4	239
269	Exploring interactions among metabolic syndrome traits. Methods and meaning. Atherosclerosis, 2010, 210, 45-47.	0.4	2
270	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 37-47.	1.0	13

#	Article	IF	Citations
271	Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis. PLoS ONE, 2010, 5, e11488.	1.1	84
272	Role of endothelial progenitor cells in diabetes mellitus. Expert Review of Endocrinology and Metabolism, 2009, 4, 575-589.	1.2	1
273	Critical confounders in the prognostic role of cellular biomarkers. Kidney International, 2009, 75, 755.	2.6	0
274	Characterizing multisegment foot kinematics during gait in diabetic foot patients. Journal of NeuroEngineering and Rehabilitation, 2009, 6, 37.	2.4	57
275	Diabetic gait and posture abnormalities: A biomechanical investigation through three dimensional gait analysis. Clinical Biomechanics, 2009, 24, 722-728.	0.5	138
276	Mechanisms and Significance of Progenitor Cell Reduction in the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2009, 7, 5-10.	0.5	18
277	Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis, 2009, 207, 213-219.	0.4	99
278	Effects of androgens on endothelial progenitor cellsin vitroandin vivo. Clinical Science, 2009, 117, 355-364.	1.8	33
279	Global Cardiovascular Risk Assessment in Different Clinical Settings. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 55-63.	1.0	13
280	Oxidative stress and vascular disease in diabetes: Is the dichotomization of insulin signaling still valid?. Free Radical Biology and Medicine, 2008, 44, 1209-1215.	1.3	40
281	Heme oxygenase-1 is an important modulator in limiting glucose-induced apoptosis in human umbilical vein endothelial cells. Life Sciences, 2008, 82, 383-392.	2.0	23
282	The metabolic syndrome, diabetes and lung dysfunction. Diabetes and Metabolism, 2008, 34, 447-454.	1.4	73
283	Endothelial dysfunction: Causes and consequences in patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2008, 82, S94-S101.	1.1	66
284	Technical notes on endothelial progenitor cells: Ways to escape from the knowledge plateau. Atherosclerosis, 2008, 197, 496-503.	0.4	233
285	Maternal Insulin Therapy Increases Fetal Endothelial Progenitor Cells During Diabetic Pregnancy. Diabetes Care, 2008, 31, 808-810.	4.3	13
286	Gender Differences in Endothelial Progenitor Cells and Cardiovascular Risk Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 997-1004.	1.1	162
287	Hypertension, Diabetes, Oxidative Stress, and Cardiovascular Remodeling: Making the Connection with p66shc. , 2008, , 279-291.		0
288	Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2627-2633.	1.1	205

#	Article	IF	Citations
289	Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women: Impact of microvascular complications, treatment, and geographic location. Diabetes Care, 2007, 30, 1241-1247.	4.3	144
290	The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 32-40.	1.1	16
291	Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis, 2007, 194, 46-54.	0.4	173
292	The good and the bad in the link between insulin resistance and vascular calcification. Atherosclerosis, 2007, 193, 241-244.	0.4	42
293	Significance of Endothelial Progenitor Cells in Subjects With Diabetes. Diabetes Care, 2007, 30, 1305-1313.	4.3	159
294	Acute effect of insulin on nitric oxide synthesis in humans: a precursor-product isotopic study. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E776-E782.	1.8	19
295	Critical Assessment of Putative Endothelial Progenitor Phenotypes. Experimental Hematology, 2007, 35, 1479-1480.	0.2	15
296	Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia, 2007, 50, 2156-2163.	2.9	92
297	Endothelial dysfunction in type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, S39-S45.	1.1	98
298	Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. Journal of Hypertension, 2006, 24, 1115-1124.	0.3	122
299	Diabetes impairs progenitor cell mobilisation after hindlimb ischaemiaâ€“reperfusion injury in rats. Diabetologia, 2006, 49, 3075-3084.	2.9	250
300	Insulin generates free radicals in human fibroblasts ex vivo by a protein kinase C-dependent mechanism, which is inhibited by pravastatin. Free Radical Biology and Medicine, 2006, 41, 473-483.	1.3	23
301	Peripheral Blood CD34 + KDR + Endothelial Progenitor Cells Are Determinants of Subclinical Atherosclerosis in a Middle-Aged General Population. Stroke, 2006, 37, 2277-2282.	1.0	204
302	Pathophysiology of Circulating Progenitor Cells in Pulmonary Disease and Parallels with Cardiovascular Disease. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 403-404.	1.4	9
303	Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. European Heart Journal, 2006, 27, 2247-2255.	1.0	220
304	Endothelial progenitor cells and erectile dysfunction. European Heart Journal, 2006, 28, 639-640.	1.0	2
305	Insulin Signaling, Glucose Metabolism, and the Angiotensin II Signaling System: Studies in Bartter's/Gitelman's syndromes. Diabetes Care, 2006, 29, 469-471.	4.3	25
306	Endothelial Progenitor Cells and the Diabetic Paradox. Diabetes Care, 2006, 29, 714-716.	4.3	87

#	Article	IF	Citations
307	Number and Function of Endothelial Progenitor Cells as a Marker of Severity for Diabetic Vasculopathy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2140-2146.	1.1	393
308	Autologous Transplantation of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells Improves Critical Limb Ischemia in Diabetes: Response to Huang et al.. Diabetes Care, 2006, 29, 478-479.	4.3	12
309	Insulin resistance: trigger or concomitant factor in the metabolic syndrome. Panminerva Medica, 2006, 48, 3-12.	0.2	11
310	Alcohol Consumption and Diabetes Mellitus. , 2005, , 501-510.		0
311	Diabetes Induces p66shcGene Expression in Human Peripheral Blood Mononuclear Cells: Relationship to Oxidative Stress. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1130-1136.	1.8	126
312	Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives. Current Diabetes Reviews, 2005, 1, 41-58.	0.6	50
313	Metformin Prevents Glucose-Induced Protein Kinase C-Â2 Activation in Human Umbilical Vein Endothelial Cells Through an Antioxidant Mechanism. Diabetes, 2005, 54, 1123-1131.	0.3	97
314	Postprandial Myocardial Perfusion in Healthy Subjects and in Type 2 Diabetic Patients. Circulation, 2005, 112, 179-184.	1.6	145
315	Arterio-venous gradient of endothelial progenitor cells across renal artery stenosis. Atherosclerosis, 2005, 182, 189-191.	0.4	13
316	Circulating Endothelial Progenitor Cells Are Reduced in Peripheral Vascular Complications of Type 2 Diabetes Mellitus. Journal of the American College of Cardiology, 2005, 45, 1449-1457.	1.2	671
317	Characterization of endothelial progenitor cells. Biochemical and Biophysical Research Communications, 2005, 336, 1-2.	1.0	42
318	Mechanisms of endothelial dysfunction in obesity. Clinica Chimica Acta, 2005, 360, 9-26.	0.5	155
319	Endothelial Dysfunction in the Metabolic Syndrome. , 2005, , 321-338.		0
320	Acute Alcohol Consumption Improves Insulin Action Without Affecting Insulin Secretion in Type 2 Diabetic Subjects. Diabetes Care, 2004, 27, 1369-1374.	4.3	49
321	Insulin Generates Free Radicals by an NAD(P)H, Phosphatidylinositol 3'-Kinase-Dependent Mechanism in Human Skin Fibroblasts Ex Vivo. Diabetes, 2004, 53, 1344-1351.	0.3	79
322	Diabetic cardiomyopathy: A metabolic perspective. American Journal of Cardiology, 2004, 93, 13-16.	0.7	86
323	In situ protein Kinase C activity is increased in cultured fibroblasts from Type 1 diabetic patients with nephropathy. Diabetologia, 2003, 46, 524-530.	2.9	19
324	Elevated non-esterified fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels. Atherosclerosis, 2003, 169, 147-153.	0.4	24

#	Article	IF	Citations
325	Moderate alcohol consumption, glucose metabolism and lipolysis: the effect on adiponectin and tumor necrosis factor Î±. Journal of Endocrinological Investigation, 2003, 26, 1213-1218.	1.8	11
326	Nonesterified fatty acids and endothelial dysfunction. International Congress Series, 2003, 1253, 139-145.	0.2	2
327	L-Arginine-Nitric Oxide Kinetics in Normal and Type 2 Diabetic Subjects: A Stable-Labelled 15N Arginine Approach. Diabetes, 2003, 52, 795-802.	0.3	60
328	Monocyte NADPH Oxidase Subunit p22phoxand Inducible Hemeoxygenase-1 Gene Expressions Are Increased in Type II Diabetic Patients: Relationship with Oxidative Stress. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1753-1759.	1.8	66
329	Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. European Heart Journal, 2003, 24, 1210-1215.	1.0	60
330	Glucose Tolerance during Moderate Alcohol Intake: Insights on Insulin Action from Glucose/Lactate Dynamics. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1233-1238.	1.8	33
331	Effects of Treatment With Sulfonylurea Drugs or Insulin on Ischemia-Induced Myocardial Dysfunction in Type 2 Diabetes. Diabetes, 2002, 51, 808-812.	0.3	89
332	Diabetic ketosis activates lymphomonocyte-inducible nitric oxide synthase. Diabetic Medicine, 2002, 19, 777-783.	1.2	12
333	Glucose Tolerance during Moderate Alcohol Intake: Insights on Insulin Action from Glucose/Lactate Dynamics. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1233-1238.	1.8	12
334	Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. European Journal of Clinical Investigation, 2001, 31, 603-609.	1.7	70
335	Hyperglycemia Acutely Increases Monocyte Extracellular Signal-Regulated Kinase Activity in Vivo in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1301-1305.	1.8	16
336	Plasma Free Fatty Acids and Endothelium-Dependent Vasodilation: Effect of Chain-Length and Cyclooxygenase Inhibition. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 793-798.	1.8	64
337	Plasma Free Fatty Acids and Endothelium-Dependent Vasodilation: Effect of Chain-Length and Cyclooxygenase Inhibition. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 793-798.	1.8	43
338	Undermodeling affects minimal model indexes: insights from a two-compartment model. American Journal of Physiology - Endocrinology and Metabolism, 1999, 276, E1171-E1193.	1.8	53
339	Effect of acute ketosis on the endothelial function of type 1 diabetic patients: the role of nitric oxide. Diabetes, 1999, 48, 391-397.	0.3	22
340	Effect of different times of administration of a single ethanol dose on insulin action, insulin secretion and redox state. Diabetic Medicine, 1999, 16, 400-407.	1.2	13
341	Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes, 1999, 48, 1316-1322.	0.3	88
342	Myocardial Dysfunction and Adrenergic Cardiac Innervation in Patients With Insulin-Dependent Diabetes Mellitus. Journal of the American College of Cardiology, 1998, 31, 404-412.	1.2	118

#	Article	IF	Citations
343	Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E592-E599.	1.8	71
344	Forearm Nitric Oxide Balance, Vascular Relaxation, and Glucose Metabolism in NIDDM Patients. Diabetes, 1997, 46, 1040-1047.	0.3	91
345	Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes, 1997, 46, 1040-1046.	0.3	35
346	Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals.. Journal of Clinical Investigation, 1996, 98, 108-115.	3.9	72
347	Epinephrine Exerts Opposite Effects on Peripheral Glucose Disposal and Glucose-Stimulated Insulin Secretion: A Stable Label Intravenous Glucose Tolerance Test Minimal Model Study. Diabetes, 1996, 45, 1373-1378.	0.3	38
348	Short-term diabetic ketosis alters n-6 polyunsaturated fatty acid content in plasma phospholipids.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1650-1653.	1.8	21
349	Ethanol impairs insulin-mediated glucose uptake by an indirect mechanism. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2285-2290.	1.8	22
350	Alcohol Intake Impairs Glucose Counterregulation During Acute Insulin-Induced Hypoglycemia in IDDM Patients: Evidence for a Critical Role of Free Fatty Acids. Diabetes, 1993, 42, 1626-1634.	0.3	59
351	Alcohol intake impairs glucose counterregulation during acute insulin-induced hypoglycemia in IDDM patients. Evidence for a critical role of free fatty acids. Diabetes, 1993, 42, 1626-34.	0.3	9
352	Epinephrine's ketogenic effect in humans is mediated principally by lipolysis. American Journal of Physiology - Endocrinology and Metabolism, 1992, 263, E250-E260.	1.8	5
353	Forearm ketone body metabolism in normal and in insulin-dependent diabetic patients. American Journal of Physiology - Endocrinology and Metabolism, 1992, 263, E261-E267.	1.8	7
354	Effects of chronic alcohol intake on carbohydrate and lipid metabolism in subjects with type ii (non-insulin-dependent) diabetes. American Journal of Medicine, 1991, 90, 70-76.	0.6	56
355	Stable-Label Intravenous Glucose Tolerance Test Minimal Model. Diabetes, 1989, 38, 1048-1055.	0.3	89
356	Contribution of 3-hydroxyisobutyrate to the measurement of 3-hydroxybutyrate in human plasma: comparison of enzymatic and gas-liquid chromatography-mass spectrometry assays in normal and in diabetic subjects.. Journal of Lipid Research, 1989, 30, 1811-1817.	2.0	29
357	Contribution of 3-hydroxyisobutyrate to the measurement of 3-hydroxybutyrate in human plasma: comparison of enzymatic and gas-liquid chromatography-mass spectrometry assays in normal and in diabetic subjects. Journal of Lipid Research, 1989, 30, 1811-7.	2.0	26
358	Type I Diabetes is Characterized by Insulin Resistance Not Only with Regard to Glucose, but also to Lipid and Aminoacid Metabolism*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 1155-1162.	1.8	53
359	Hyperglycemia Acutely Increases Monocyte Extracellular Signal-Regulated Kinase Activity in Vivo in Humans. , 0, .		5
360	Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study. Diabetes Therapy, 0, , .	1.2	0